CSL Limited, a biotechnology company that produce many of its biological products from plasma, is diversifying its portfolio and its drug pipeline through its largest ever acquisition: the purchase of ...

CSL is well ahead of Grifols in evolving its business to recombinant products and Grifols is not pursuing gene therapy at present. CSL is also the only player with a direct presence in China which is ...

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring ...

Ladies and gentlemen, good morning and welcome to CSL's Full-Year Results Call for Fiscal 2023. It's Mark Dehring speaking, and joining me online is Paul McKenzie, CSL's Chief Executive Officer; Joy ...

Dave Ross - Senior Vice President and General Manager, CSL Seqirus Hervé Gisserot - Senior Vice President and General Manager, CSL Vifor Thank you for standing by and welcome to the CSL Limited Half ...

Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vifor Pharma Ltd (SIX:VIFN; ISIN:CH0364749348), a global specialty pharmaceutical company with leadership in iron deficiency, ...

In a report released today, Laura Sutcliffe from UBS maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of A$350.00. The company’s shares closed yesterday at $201.50.

RBC Capital Markets thinks CSL is a bargain at current levels. The post Check out this CSL share price forecast for 2026.

CSL Ltd (ASX:CSL) has seen shares fall nearly half a percent in afternoon trades on Thursday as the company responds to Trump’s US tariffs. For now, that decline is subdued, because of as of yet the ...

Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt ...